Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 218

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 218
---
 shareholders' equity (deficiency) |       |     |    1,893,057 |   |     |      282,652 |   |
| Commitments and contingencies                           |    12 |     |              |   |     |              |   |
| Subsequent events                                       |    16 |     |              |   |     |              |   |

Approved on behalf of the Board:

| "Signed"                     | "Signed"                 |
| Director - Robert Ciaruffoli | Director - Frank Lavelle |

The accompanying notes are an integral part of these consolidated financial statements.

<div align='center'>F-23

Medicus Pharma Ltd.
Consolidated Statements of Loss and Comprehensive Loss
(expressed in United States dollars, except number of shares)</div>

|                                                      |       |     |       2023 |   |     | For the years ended December 31, 
                             2022 |   |
|:-----------------------------------------------------|------:|:----|-----------:|:--|:----|---------------------------------:|:--|
|                                                      | Notes |     |          $ |   |     |                                $ |   |
| Operating expenses                                   |       |     |            |   |     |                                  |   |
| General and administrative                           |       |     |  2,366,202 |   |     |                          332,032 |   |
| Research and development                             |       |     |    193,578 |   |     |                          646,384 |   |
| Share-based compensation                             |     9 |     |    146,671 |   |     |                                - |   |
| Total operating expenses                             |       |     |  2,706,451 |   |     |                          978,416 |   |
| Loss from operations                                 |       |     | (2,706,451 | ) |     |                         (978,416 | ) |
| Finance expense, net                                 |     6 |     |    500,579 |   |     |                          713,966 |   |
| Listing expense                                      |     4 |     |  3,271,462 |   |     |                                - |   |
| Net loss and comprehensive loss for the year         |       |     | (6,478,492 | ) |     |                       (1,692,382 | ) |
| Loss per share - basic and diluted                   |    10